Developer docs
API playgroundTry for free, no card

Search company profiles

Gamida Cell

Full company profile

uuid0003se3

Namestring
Gamida Cell
Legal namestring
Gamida Cell Ltd.
Websiteurl
gamida-cell.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Gamida Cell Ltd. is a commercial-stage biopharmaceutical company headquartered in Jerusalem, Israel, with US commercial operations based in Naples, Florida, and a wholly owned GMP manufacturing facility in Kiryat Gat, Israel. Founded in 2001 (incorporated as a subsidiary operating under parent Ayrmid Ltd., a UK entity, since November 2024), the company develops and commercializes cell therapies and adjunctive products for hematologic malignancies, severe aplastic anemia, and stem cell transplantation. Its core commercial products are Omisirge (Omidubicel-onlv), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood and FDA-approved for hematologic malignancies (May 2023) and severe aplastic anemia (December 2025), and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma, in-licensed from BioLineRx in November 2024.

The company is built around a proprietary nicotinamide (NAM) cell-expansion platform that enhances and expands stem cells while preserving intrinsic functional properties such as homing, retention in bone marrow, and metabolic fitness. This platform underpins Omisirge and supports the company's positioning in the allogeneic transplant market, where it addresses patients who lack a matched donor. Business model revenue comes from one-time product sales of FDA-approved cell therapies and mobilization agents to US transplant centers via a direct specialty field-sales organization, supplemented by international distribution partnerships (ACA Pharma covering 15 Greater China and Southeast Asia markets; Ariti S.A. for Greece and Cyprus) and licensing royalties. Patient support is delivered through the Gamida Cell Assist program, which provides enrollment, order tracking, reimbursement, and financial assistance services. A new US manufacturing partnership with RoslinCT (Hopkinton, MA) is being established to supply Omisirge commercially beginning in 2027.

Short descriptiontext

Gamida Cell Ltd. is a commercial-stage biopharmaceutical company developing and commercializing FDA-approved cell therapies (Omisirge) and stem cell mobilization agents (APHEXDA) for hematologic malignancies, severe aplastic anemia, and multiple myeloma patients requiring transplantation, sold primarily to US transplant centers and via international distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy pharmaceuticals, stem cell transplantation, hematologic disease treatments, allogeneic cell therapy, cord blood therapies
Industry4 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Omisirge Sales
TypeOne Time License
Description

Revenue from sales of Omisirge (Omidubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy for patients requiring stem cell transplant. Marketed to transplant centers and hospitals in the US.

gamida-cell.com
2APHEXDA Sales
TypeOne Time License
Description

Revenue from sales of APHEXDA (motixafortide), an FDA-approved CXCR4 antagonist for stem cell mobilization in multiple myeloma. Licensed from BioLineRx for commercialization in all territories excluding solid tumors and Asia.

gamida-cell.com
3International Distribution Royalties
TypeLicensing Royalties
Description

Revenue from international distribution partnerships including Ayrmid's agreements with ACA Pharma for Greater China/Southeast Asia and Ariti for Greece/Cyprus.

pharmiweb.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1APHEXDA (motixafortide)
Description

FDA-approved CXCR4 antagonist indicated in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.

gamida-cell.com
+1 more record
Core offering1 text field

Gamida Cell develops and commercializes cell therapies for patients with blood cancers and serious hematologic diseases. Its commercial products include Omisirge (omidoubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma. The company also operates the Gamida Cell Assist patient support program and conducts ongoing clinical development for severe aplastic anemia and sickle cell disease indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Median time to neutrophil recovery: 8-11 days in SAA patients
+6 more records
Product overview1 text field

Gamida Cell offers a focused portfolio of FDA-approved cell therapy products for hematologic conditions. The core products are Omisirge (Omidubicel onlv), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood, and APHEXDA (motixafortide), a CXCR4 antagonist for stem cell mobilization in multiple myeloma. These are complemented by Gamida Cell Assist, a patient support services program. The company leverages its proprietary nicotinamide (NAM) technology to enhance and expand stem cells while maintaining their intrinsic properties.

Product and service1 record
1Omisirge (omidoubicel-onlv)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Gamida Cell is a member company of ABIA, a new coalition of approximately 50 biotechnology companies formed to develop a national policy strategy to strengthen American biotech innovation amid rising competition from China.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-09
Description

Exclusive distributor appointed for Omisirge across 15 markets in Greater China and Southeast Asia including Mainland China, Hong Kong, Singapore, Vietnam, and Indonesia. ACA Pharma holds exclusive rights to register and distribute the therapy.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-05
Description

Exclusive distribution agreement with Greece-based pharmaceutical company Ariti S.A. for distribution of Omisirge in Greece and Cyprus. Ariti will leverage its local market infrastructure and hematology expertise to support early access schemes.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-20
Description

Exclusive license agreement for Ayrmid/Gamida Cell to commercialize APHEXDA (motixafortide) across all indications excluding solid tumors and all territories other than Asia. BioLineRx received $10 million upfront payment plus up to $87 million in commercial milestones and 18-23% royalties on net sales.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic manufacturing partnership for future production of Omisirge in the US. Technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art cell therapy CGMP manufacturing facility in Hopkinton, MA beginning in 2027.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Allogene Therapeutics is a clinical-stage allogeneic CAR-T developer targeting hematologic malignancies with off-the-shelf cell therapy products, directly comparable to Gamida Cell's allogeneic, off-the-shelf Omisirge approach in blood cancers.

TypeDirect peer
Description

Iovance commercializes cell therapies for hematologic and solid tumors and represents a leading direct peer in the cell therapy commercialization space, operating in the same disease setting (hematologic malignancies) as Gamida Cell.

TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf, iPSC-derived cell therapies for cancer and immune disorders, sharing Gamida Cell's allogeneic, off-the-shelf cell therapy philosophy and heme-oncology focus.

TypeDirect peer
Description

Adaptimmune develops engineered T-cell therapies (SPEAR T-cells) for hematologic malignancies and solid tumors, overlapping with Gamida Cell's cell therapy approach to blood cancer treatment.

TypeBroad incumbent
Description

Kite Pharma, a Gilead subsidiary, markets Yescarta and Tecartus autologous CAR-T therapies for lymphoma/leukemia, representing a broader incumbent cell therapy player whose commercial CAR-T products compete for the same hematologic transplant patient pool served by Omisirge.

6Bristol Myers Squibb (Cell Therapy)
TypeBroad incumbent
Description

BMS markets Breyanzi and Abecma CAR-T cell therapies for lymphoma and multiple myeloma, positioning it as a broad incumbent cell therapy competitor alongside Gamida Cell in hematologic malignancies and multiple myeloma.

TypeBroad incumbent
Description

Novartis commercializes the first FDA-approved CAR-T Kymriah for pediatric/young adult ALL and DLBCL, an established broad incumbent cell therapy player whose autologous CAR-T competes with Gamida Cell's allogeneic Omisirge in similar indications.

TypeEmerging player
Description

CRISPR Therapeutics co-developed Casgevy, the first FDA-approved CRISPR gene therapy for sickle cell disease, where motixafortide/APHEXDA serves as a stem cell mobilization enabler—creating a complementary commercial relationship relevant to Gamida Cell's APHEXDA.

TypeDirect peer
Description

Mesoblast develops allogeneic cellular medicines (remestemcel-L) for inflammatory and hematologic conditions including pediatric steroid-refractory acute graft-versus-host disease, a direct peer in the allogeneic cell therapy for hematologic disease space.

10Bluebird Bio
TypeEmerging player
Description

Bluebird bio develops gene and cell therapies for severe genetic diseases including sickle cell (Lyfgenia); although focused on gene-modified approaches, its commercial launch in sickle cell directly drives demand for stem cell mobilization agents like APHEXDA.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gamida Cell

Cell Therapy Pharmaceuticalsgamida-cell.com

Gamida Cell Ltd. is a commercial-stage biopharmaceutical company developing and commercializing FDA-approved cell therapies (Omisirge) and stem cell mobilization agents (APHEXDA) for hematologic malignancies, severe aplastic anemia, and multiple myeloma patients requiring transplantation, sold primarily to US transplant centers and via international distribution partners.

What Gamida Cell does

Gamida Cell Ltd. is a commercial-stage biopharmaceutical company headquartered in Jerusalem, Israel, with US commercial operations based in Naples, Florida, and a wholly owned GMP manufacturing facility in Kiryat Gat, Israel. Founded in 2001 (incorporated as a subsidiary operating under parent Ayrmid Ltd., a UK entity, since November 2024), the company develops and commercializes cell therapies and adjunctive products for hematologic malignancies, severe aplastic anemia, and stem cell transplantation. Its core commercial products are Omisirge (Omidubicel-onlv), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood and FDA-approved for hematologic malignancies (May 2023) and severe aplastic anemia (December 2025), and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma, in-licensed from BioLineRx in November 2024.

The company is built around a proprietary nicotinamide (NAM) cell-expansion platform that enhances and expands stem cells while preserving intrinsic functional properties such as homing, retention in bone marrow, and metabolic fitness. This platform underpins Omisirge and supports the company's positioning in the allogeneic transplant market, where it addresses patients who lack a matched donor. Business model revenue comes from one-time product sales of FDA-approved cell therapies and mobilization agents to US transplant centers via a direct specialty field-sales organization, supplemented by international distribution partnerships (ACA Pharma covering 15 Greater China and Southeast Asia markets; Ariti S.A. for Greece and Cyprus) and licensing royalties. Patient support is delivered through the Gamida Cell Assist program, which provides enrollment, order tracking, reimbursement, and financial assistance services. A new US manufacturing partnership with RoslinCT (Hopkinton, MA) is being established to supply Omisirge commercially beginning in 2027.

Gamida Cell firmographics

Firmographics
Name
Gamida Cell
Legal name
Gamida Cell Ltd.
Website
https://gamida-cell.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Gamida Cell Ltd. is a commercial-stage biopharmaceutical company developing and commercializing FDA-approved cell therapies (Omisirge) and stem cell mobilization agents (APHEXDA) for hematologic malignancies, severe aplastic anemia, and multiple myeloma patients requiring transplantation, sold primarily to US transplant centers and via international distribution partners.
Ownership category
akta.pro rank

Gamida Cell industry classification

Industry
Product category
Cell Therapy Pharmaceuticals
NAICS
Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)

Keywords

  • Cell therapy pharmaceuticals
  • Stem cell transplantation
  • Hematologic disease treatments
  • Allogeneic cell therapy
  • Cord blood therapies

Where Gamida Cell is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Gamida Cell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Omisirge Sales: Revenue from sales of Omisirge (Omidubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy for patients requiring stem cell transplant. Marketed to transplant centers and hospitals in the US.
  2. APHEXDA Sales: Revenue from sales of APHEXDA (motixafortide), an FDA-approved CXCR4 antagonist for stem cell mobilization in multiple myeloma. Licensed from BioLineRx for commercialization in all territories excluding solid tumors and Asia.
  3. International Distribution Royalties: Revenue from international distribution partnerships including Ayrmid's agreements with ACA Pharma for Greater China/Southeast Asia and Ariti for Greece/Cyprus.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Gamida Cell product offering

Product offering

Core offering

Gamida Cell develops and commercializes cell therapies for patients with blood cancers and serious hematologic diseases. Its commercial products include Omisirge (omidoubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma. The company also operates the Gamida Cell Assist patient support program and conducts ongoing clinical development for severe aplastic anemia and sickle cell disease indications.

Product overview

Gamida Cell offers a focused portfolio of FDA-approved cell therapy products for hematologic conditions. The core products are Omisirge (Omidubicel onlv), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood, and APHEXDA (motixafortide), a CXCR4 antagonist for stem cell mobilization in multiple myeloma. These are complemented by Gamida Cell Assist, a patient support services program. The company leverages its proprietary nicotinamide (NAM) technology to enhance and expand stem cells while maintaining their intrinsic properties.

Differentiator

Problem solved

Functional benefit

Brands

  • APHEXDA (motixafortide): FDA-approved CXCR4 antagonist indicated in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.
  • Gamida Cell Assist

Products and services

  • Omisirge (omidoubicel-onlv)

Quantifiable outcome

  • Median time to neutrophil recovery: 8-11 days in SAA patients
  • +6 more outcomes

Companies that use Gamida Cell

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles1 record

Gamida Cell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Gamida Cell partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • American Biotech Innovation Alliance (ABIA)minorStrategic or Co-development Partner · 5 May 2026Gamida Cell is a member company of ABIA, a new coalition of approximately 50 biotechnology companies formed to develop a national policy strategy to strengthen American biotech innovation amid rising competition from China.
  • ACA PharmacoreChannel Partner/ Reseller/ Distributor · 9 February 2026Exclusive distributor appointed for Omisirge across 15 markets in Greater China and Southeast Asia including Mainland China, Hong Kong, Singapore, Vietnam, and Indonesia. ACA Pharma holds exclusive rights to register and distribute the therapy.
  • Ariti S.A.coreChannel Partner/ Reseller/ Distributor · 5 February 2026Exclusive distribution agreement with Greece-based pharmaceutical company Ariti S.A. for distribution of Omisirge in Greece and Cyprus. Ariti will leverage its local market infrastructure and hematology expertise to support early access schemes.
  • BioLineRxcoreOEM/ Whitelabel/ Licensing Partner · 20 November 2024Exclusive license agreement for Ayrmid/Gamida Cell to commercialize APHEXDA (motixafortide) across all indications excluding solid tumors and all territories other than Asia. BioLineRx received $10 million upfront payment plus up to $87 million in commercial milestones and 18-23% royalties on net sales.
  • RoslinCTcoreStrategic or Co-development PartnerStrategic manufacturing partnership for future production of Omisirge in the US. Technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art cell therapy CGMP manufacturing facility in Hopkinton, MA beginning in 2027.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Gamida Cell competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Allogene Therapeutics is a clinical-stage allogeneic CAR-T developer targeting hematologic malignancies with off-the-shelf cell therapy products, directly comparable to Gamida Cell's allogeneic, off-the-shelf Omisirge approach in blood cancers.
  • Iovance Biotherapeutics: Iovance commercializes cell therapies for hematologic and solid tumors and represents a leading direct peer in the cell therapy commercialization space, operating in the same disease setting (hematologic malignancies) as Gamida Cell.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf, iPSC-derived cell therapies for cancer and immune disorders, sharing Gamida Cell's allogeneic, off-the-shelf cell therapy philosophy and heme-oncology focus.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell therapies (SPEAR T-cells) for hematologic malignancies and solid tumors, overlapping with Gamida Cell's cell therapy approach to blood cancer treatment.
  • Mesoblast: Mesoblast develops allogeneic cellular medicines (remestemcel-L) for inflammatory and hematologic conditions including pediatric steroid-refractory acute graft-versus-host disease, a direct peer in the allogeneic cell therapy for hematologic disease space.

Broad incumbents

  • Kite Pharma (Gilead): Kite Pharma, a Gilead subsidiary, markets Yescarta and Tecartus autologous CAR-T therapies for lymphoma/leukemia, representing a broader incumbent cell therapy player whose commercial CAR-T products compete for the same hematologic transplant patient pool served by Omisirge.
  • Bristol Myers Squibb (Cell Therapy): BMS markets Breyanzi and Abecma CAR-T cell therapies for lymphoma and multiple myeloma, positioning it as a broad incumbent cell therapy competitor alongside Gamida Cell in hematologic malignancies and multiple myeloma.
  • Novartis (Kymriah): Novartis commercializes the first FDA-approved CAR-T Kymriah for pediatric/young adult ALL and DLBCL, an established broad incumbent cell therapy player whose autologous CAR-T competes with Gamida Cell's allogeneic Omisirge in similar indications.

Emerging players

  • CRISPR Therapeutics: CRISPR Therapeutics co-developed Casgevy, the first FDA-approved CRISPR gene therapy for sickle cell disease, where motixafortide/APHEXDA serves as a stem cell mobilization enabler—creating a complementary commercial relationship relevant to Gamida Cell's APHEXDA.
  • Bluebird Bio: Bluebird bio develops gene and cell therapies for severe genetic diseases including sickle cell (Lyfgenia); although focused on gene-modified approaches, its commercial launch in sickle cell directly drives demand for stem cell mobilization agents like APHEXDA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Gamida Cell social profiles

Digital presence

Gamida Cell compliance and trust

Trust signal

Compliance1 record

Gamida Cell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gamida Cell leadership team

Management profile

Number of profiles

Profiles15 records

Gamida Cell subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Gamida Cell funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gamida Cell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gamida Cell

What does Gamida Cell do?

Gamida Cell develops and commercializes cell therapies for patients with blood cancers and serious hematologic diseases. Its commercial products include Omisirge (omidoubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma. The company also operates the Gamida Cell Assist patient support program and conducts ongoing clinical development for severe aplastic anemia and sickle cell disease indications.

Is Gamida Cell a public or private company?

Gamida Cell is a private company. It is classified as corporate owned and is currently operating.

When was Gamida Cell founded?

Gamida Cell was founded in 2001. It employs 51 to 100 people.

Where is Gamida Cell based?

Gamida Cell is headquartered in Boston, United States, in the North America region.

How does Gamida Cell make money?

Three revenue lines are on record. Omisirge Sales are the primary driver. The others are APHEXDA Sales and international Distribution Royalties.

Who are Gamida Cell's main competitors?

Direct peers on record are Allogene Therapeutics, Iovance Biotherapeutics, Fate Therapeutics, Adaptimmune Therapeutics and Mesoblast. Broad incumbents are Kite Pharma (Gilead), Bristol Myers Squibb (Cell Therapy) and Novartis (Kymriah). Emerging players are CRISPR Therapeutics and Bluebird Bio.

Does Gamida Cell have an API?

No public API is recorded for Gamida Cell.

What industry is Gamida Cell in?

Gamida Cell's product category is Cell Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 621991 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAplastic Anemia Market Growth Outlook 2036: Epidemiology, Pipeline Therapies, And Revenue Forecast Delveinsight Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengruiDelveInsight's report projects the aplastic anemia market to grow from about $300 million in 2025 to over $300 million by 2036, with a 2% CAGR. The market is expected to decline from 2026 onward due to generic PROMACTA entry, and Japan led incident cases in 2025.Managed Healthcare ExecutiveFDA Approves Omisirge to Reduce Infection Risk in Blood Cancer Patients Undergoing Stem Cell TransplantThe FDA has approved Omisirge (omidubicel-onlv), a stem cell therapy developed by Gamida Cell, to accelerate neutrophil recovery and reduce infection risk in patients undergoing cord blood transplantation for blood cancers. The treatment is priced at $338,000 per dose and is expected to be delivered to transplant centers within 30 days of manufacturing.GlobeNewswireOmisirge (Gamida Cell) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035FThe Omisirge market research report profiles Gamida Cell's FDA-approved cell therapy for allogeneic hematopoietic stem cell transplantation, indicated for leukemia, lymphoma, myeloma, and related blood disorders. In May 2023, the FDA approved Omisirge to accelerate neutrophil recovery and reduce infection risk in transplant patients, and in March 2025 Ayrmid Pharma Ltd. partnered with RoslinCT to scale manufacturing for commercial supply. The report projects significant market expansion driven by rising demand for personalized cell therapies, growing adoption of expanded cord blood transplants, and increased investment in regenerative medicine infrastructure.pharmaphorumASH: FDA okays Gamida aplastic anaemia therapy as data dropsThe FDA approved Gamida Cell's Omisirge (omidubicel) as the first cell therapy for severe aplastic anaemia, based on positive results from a pivotal trial presented at the ASH congress. In the study of 19 patients aged six and over, 95% achieved rapid recovery of infection-fighting neutrophil cells with a median time to recovery of eight days, and 94% overall survival with no cases of severe or chronic graft-versus-host disease. The FDA's Center for Biologics Evaluation and Research called the approval 'revolutionary' for patients who previously had almost no treatment options when no matched stem cell donor was available.PharmiWeb.comFDA approves Omisirge(R) as First Approved Cell Therapy to Treat Severe Aplastic AnemiaAyrmid Ltd., the parent company of Gamida Cell Inc., announced FDA approval for Omisirge (omidubicel-onlv) as a cell therapy for Severe Aplastic Anemia, based on a clinical study demonstrating 86% neutrophil recovery and 92% disease-free survival. The approval expands the use of Omisirge beyond its initial 2023 hematological malignancy indication and offers a transplant option for SAA patients who lack matched related donors. Ayrmid has partnered with RoslinCT to establish additional manufacturing capacity for Omisirge at its facility in Hopkinton, MA, beginning in 2027.BioSpaceGamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with OmidubicelAyrmid Ltd. and its subsidiary Gamida Cell Inc. announced positive interim clinical trial results for omidubicel, a stem cell transplant therapy for Severe Aplastic Anemia, presented at the 2025 AABB Annual Meeting. The study showed 92.9% of patients (13 of 14) achieved rapid neutrophil recovery with a median time of 7 days, a 92.3% disease-free survival rate, and no severe graft-versus-host disease. The company is preparing for FDA review with a PDUFA target action date of December 10, 2025.BioinformantUtilization of Umbilical Cord Blood in HSCT versus Regenerative Medicine (Percentage Breakdown)Umbilical cord blood utilization is shifting from traditional hematopoietic stem cell transplantation, which accounts for 83.7% of global market revenue, toward regenerative medicine applications comprising the remaining 16.3%. Companies such as Nohla Therapeutics, Gamida Cells, Angiocrine Bioscience, and BioIntegrate LLC are actively developing novel cellular therapies for conditions like spinal cord injury and diabetes, while Cord Blood Registry facilitates research by releasing stored units.BiolinerxBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.BioLineRx granted Ayrmid an exclusive license to commercialize APHEXDA (motixafortide) outside Asia, receiving $10 million upfront and up to $87 million in milestones plus 18-23% royalties. BioLineRx retains solid tumor development rights and received a $9 million equity investment. The equity investment is expected to close today.PR NewswireBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.BioLineRx granted Ayrmid an exclusive license to commercialize APHEXDA (motixafortide) outside Asia, receiving $10 million upfront and up to $87 million in milestones plus 18-23% royalties. BioLineRx also received a $9 million equity investment from Highbridge Capital Management funds.Business Wire BlogGamida Cell Announces New Leadership Under Ownership of Highbridge Capital ManagementGamida Cell appointed Dr. Joe Wiley as CEO, Rory Nealon as CFO, and Sheila Frame as Chief Commercial Officer after a restructuring with Highbridge Capital Management. Highbridge invested $30 million in new capital, and the company now operates as a wholly owned subsidiary of Ayrmid Limited. The leadership aims to expand access to Omisirge for patients.